版本:
中国

BRIEF-Merck receives FDA approval of ISENTRESS HD for treatment of HIV-1 infection in appropriate patients

May 30 Merck & Co Inc:

* Merck receives FDA approval of Isentress HD (raltegravir), a new once-daily option, in combination with other antiretroviral agents, for the treatment of hiv-1 infection in appropriate patients

* Merck receives FDA approval of Isentress HD (raltegravir), a new once-daily option, in combination with other antiretroviral agents, for the treatment of hiv-1 infection in appropriate patients

* Merck & Co Inc says Merck anticipates isentress HD to be available in pharmacies in approximately four weeks

* Merck & Co Inc says price of Isentress HD will be same as Isentress twice daily Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐